| 10/13/2026 7:36 AM | SAB Biotherapeutics (1833214) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/21/2026 3:30 PM | SAB Biotherapeutics (1833214) Filer | Form 424B3 | |
| 08/14/2026 4:20 PM | PERCEPTIVE ADVISORS LLC (1224962) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13G/A | |
| 08/14/2026 3:52 PM | Caligan Partners LP (1727492) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13G/A | |
| 08/14/2026 10:04 AM | SAB Biotherapeutics (1833214) Subject Woodline Partners LP (1784547) Filed by | Form SCHEDULE 13G/A | |
| 08/14/2026 5:08 AM | BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13G/A | |
| 08/12/2026 11:08 AM | Adage Capital Management, L.P. (1535978) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13G | |
| 08/06/2026 6:56 AM | SAB Biotherapeutics (1833214) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/07/2026 7:15 AM | SAB Biotherapeutics (1833214) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/26/2026 4:20 PM | Kropotova Alexandra (1825323) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/18/2026 3:35 PM | SAB Biotherapeutics (1833214) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for SABSW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 05/15/2026 10:17 AM | Caligan Partners LP (1727492) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13G | |
| 05/15/2026 5:28 AM | BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13G | |
| 05/12/2026 6:35 AM | SAB Biotherapeutics (1833214) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/04/2026 3:35 PM | SAB Biotherapeutics (1833214) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/01/2026 3:57 PM | MILLENNIUM MANAGEMENT LLC (1273087) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13G | |
| 04/22/2026 7:13 AM | SAB Biotherapeutics (1833214) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/31/2026 4:35 PM | SAB Biotherapeutics (1833214) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 03/25/2026 3:35 PM | Kropotova Alexandra (1825323) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/23/2026 3:25 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13D/A | |
| 03/10/2026 6:35 AM | SAB Biotherapeutics (1833214) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/09/2026 4:10 PM | SAB Biotherapeutics (1833214) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/17/2026 7:47 AM | RTW INVESTMENTS, LP (1493215) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13G/A | |
| 02/05/2026 3:45 PM | Bausch Christoph Lawrence (1889981) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/05/2026 3:50 PM | Reich Samuel J (1394645) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/05/2026 3:55 PM | SAB Biotherapeutics (1833214) Issuer Sullivan Eddie Joe (1889712) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/22/2026 3:34 PM | PERCEPTIVE ADVISORS LLC (1224962) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13G | |
| 01/07/2026 11:15 PM | SAB Biotherapeutics (1833214) Filer | Form EFFECT | |
| 01/07/2026 3:40 PM | SAB Biotherapeutics (1833214) Issuer ZACCARDELLI DAVID (1627642) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/07/2026 3:41 PM | Jain Rita (1707797) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/07/2026 3:35 PM | SAB Biotherapeutics (1833214) Issuer ZACCARDELLI DAVID (1627642) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 01/07/2026 3:36 PM | Jain Rita (1707797) Reporting SAB Biotherapeutics (1833214) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 01/07/2026 7:30 AM | SAB Biotherapeutics (1833214) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/30/2025 9:08 AM | SAB Biotherapeutics (1833214) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 12/18/2025 3:45 PM | Ellias Helen K. (2001600) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/18/2025 3:50 PM | Lucera Erick (1697616) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/18/2025 3:53 PM | Polvino William James (1889459) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/18/2025 3:40 PM | Link David (2085171) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/18/2025 3:43 PM | Giberson Scott (1937585) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/15/2025 3:30 PM | SAB Biotherapeutics (1833214) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 12/12/2025 3:45 PM | Kropotova Alexandra (1825323) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
A new income category is drawing serious money - here's why (Ad) Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion.
These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need. Watch the short briefing to see how this income approach works |
| 11/12/2025 3:45 PM | SAB Biotherapeutics (1833214) Filer | Form 424B3 | |